“The future of autoimmunity is being reprogrammed in real time, and iPSC CAR‑T cells are helping to write the code.”Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, speaks with John (Bobby) Goulding, Director, Corporate Strategy, Fate Therapeutics, who takes an in‑depth look at induced pluripotent stem cell (iPSC)-derived allogeneic CAR‑T cells and their potential clinical application in autoimmune disease, including safety‑by‑design considerations, clinical trial considerations, manufacturing scalability, and democratizing outpatient access.
John Goulding (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: